Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKuo‐Kai ChinBBBrian BallTHTamanna Haque

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals low response rates and poor survival outcomes in R/R AML post-MENINi, suggesting new treatment strategies are critical.

Key Points

  • Overall survival after non-investigational therapy was just 4.4 months, indicating the need for better treatments.
  • Survivors achieving complete remission or overall response had improved median overall survival of 15.4 months versus 3.4 months.
  • Analysis included a retrospective review of patients receiving post-MENINi treatments at four U.S. academic centers.
  • Further research is needed to explore effective treatment sequencing in relapsed or refractory AML patients.

Cite This Study

Chin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e4https://doi.org/10.1182/blood-2025-39
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study2025 · 1 citations
  2. 2The role of menin inhibitors in acute myeloid leukemia2025 · 2 citations
  3. 3Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review2025 · 7 citations
  4. 4Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis2025
  5. 5A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias2025